These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17194579)

  • 41. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake.
    Baker M; Parton T
    Xenobiotica; 2007; 37(10-11):1110-34. PubMed ID: 17968739
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of time step simulations and difference equations (TSSADEQ) in modeling heparin pharmacokinetics.
    Wachsman M; Mielke CH; Hayes JA; Baker D
    J Clin Pharmacol; 2000 Oct; 40(10):1121-8. PubMed ID: 11028251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
    De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
    Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Digoxin-like immunoreactive substances in hypertrophic cardiomyopathy.
    Mahon N; Mckenna WJ
    Eur Heart J; 2000 Jul; 21(13):1034-6. PubMed ID: 10843817
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effects of digoxin and corglycon on ion currents in neuronal membrane of snail (Lymnaea stagnalis)].
    Vislobokov AI; Ignatov IuD; Mel'nikov KN
    Eksp Klin Farmakol; 2008; 71(5):19-24. PubMed ID: 19093366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol.
    Carlton LD; Pollack GM; Brouwer KL
    J Pharm Sci; 1996 May; 85(5):473-7. PubMed ID: 8742937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiac output and systemic transit time dispersion as determinants of circulatory mixing time: a simulation study.
    Weiss M
    J Appl Physiol (1985); 2009 Aug; 107(2):445-9. PubMed ID: 19498099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered distribution of digoxin in renal failure--a cause of digoxin toxicity?
    Aronson JK; Grahame-Smith DG
    Br J Clin Pharmacol; 1976 Dec; 3(6):1045-51. PubMed ID: 22216528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug-receptor relationships, selection of therapeutic goals, and adaptive control of pharmacokinetic systems.
    Jelliffe RW
    Fed Proc; 1987 Jun; 46(8):2494-501. PubMed ID: 3297797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of distributed and compartmental models of drug disposition: assessment of tissue uptake kinetics.
    Weiss M
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):505-12. PubMed ID: 27534939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Residence time dispersion as a general measure of drug distribution kinetics: estimation and physiological interpretation.
    Weiss M
    Pharm Res; 2007 Nov; 24(11):2025-30. PubMed ID: 17510754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations.
    Khor SP; Mayersohn M
    Drug Metab Dispos; 1991; 19(2):478-85. PubMed ID: 1676658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular pharmacokinetics: effects of cytoplasmic diffusion and binding on organ transit time distribution.
    Weiss M
    J Pharmacokinet Biopharm; 1999 Jun; 27(3):233-56. PubMed ID: 10728488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of digoxin blood levels.
    Greenlaw CW; Haug MT; Geiger GS
    Am J Hosp Pharm; 1981 Feb; 38(2):168, 170. PubMed ID: 7211881
    [No Abstract]   [Full Text] [Related]  

  • 55. Modeling of drug response in individual subjects.
    Kelman AW; Whiting B
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):115-30. PubMed ID: 7431218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of digoxin in hyperthryoid patients.
    Koup JR
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):236. PubMed ID: 7390673
    [No Abstract]   [Full Text] [Related]  

  • 57. Distribution Clearance: Significance and Underlying Mechanisms.
    Weiss M
    Pharm Res; 2024 Jul; 41(7):1391-1400. PubMed ID: 38981900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges.
    Vagos M; van Herck IGM; Sundnes J; Arevalo HJ; Edwards AG; Koivumäki JT
    Front Physiol; 2018; 9():1221. PubMed ID: 30233399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exponential tails of drug disposition curves: reality or appearance?
    Weiss M
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):49-54. PubMed ID: 24338373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y; Hu ZY
    Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.